The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
L | Antineoplastic and immunomodulating agents | |
2
|
L04 | Immunosuppressants | |
3
|
L04A | Immunosuppressants | |
4
|
L04AJ | Complement inhibitors | |
5
|
L04AJ02 |
| Active Ingredient |
|---|
|
Ravulizumab is a monoclonal antibody IgG2/4K that specifically binds to the complement protein C5, thereby inhibiting its cleavage to C5a (the proinflammatory anaphylatoxin) and C5b (the initiating subunit of the terminal complement complex [C5b-9]) and preventing the generation of the C5b-9. Ravulizumab preserves the early components of complement activation that are essential for opsonisation of microorganisms and clearance of immune complexes. |
| Document | Type | Information Source | |
|---|---|---|---|
| ULTOMIRIS Concentrate for solution for infusion | MPI, EU: SmPC | European Medicines Agency (EU) | |
| ULTOMIRIS Solution for injection | MPI, US: SPL/PLR | FDA, National Drug Code (US) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.